High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 1, 2019

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2023

Conditions
Metastatic Pancreatic CancerPancreatic CancerPancreas CancerPancreatic Adenocarcinoma ResectablePancreatic Ductal AdenocarcinomaPancreatic Metastasis
Interventions
DRUG

Ascorbic Acid

25, 37.5, 56.25 or 75 grams/m2

DRUG

Paclitaxel protein-bound

125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days

DRUG

Cisplatin

25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days

DRUG

Gemcitabine

1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days

Trial Locations (6)

30214

Piedmont Cancer Institute, PC, Fayetteville

30265

Piedmont Cancer Institute, PC, Newnan

30318

Piedmont Cancer Institute, PC, Atlanta

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

85258

HonorHealth Research Institute, Scottsdale

92093

University of California San Diego Moores Cancer Center, San Diego

All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

Stand Up To Cancer

OTHER

collaborator

Lustgarten Foundation

OTHER

collaborator

Destroy Pancreatic Cancer

OTHER

collaborator

Translational Genomics Research Institute

OTHER

collaborator

HonorHealth Research Institute

OTHER

lead

Medical College of Wisconsin

OTHER